XML 80 R55.htm IDEA: XBRL DOCUMENT v3.25.4
ADDITIONAL BALANCE SHEET DETAIL - Schedule of Accrued Expenses and other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Payables and Accruals [Abstract]    
Product revenue allowances $ 7,916 $ 9,657
Product rebates 64,674 6,070
Product return provisions, current portion 2,375 5,295
Compensation and related benefits 11,018 9,194
Operating lease liabilities, current portion 3,548 5,400
Royalties due to Panion & BF Biotech, Inc. 3,924 3,543
Liability related to sale of future royalties, current portion 1,664 2,039
Professional fees 1,597 1,452
Accrued manufacturing costs 1,808 1,468
BioVectra, Inc. termination fees, current portion 0 7,204
Settlement royalties liability, current portion 12,516 5,924
Clinical trial costs 1,188 1,885
Restructuring costs, current portion 0 489
Payments due to Q32 5,000 0
Other 4,488 3,840
Total accrued expenses and other current liabilities $ 121,716 $ 63,460
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Total accrued expenses and other current liabilities Total accrued expenses and other current liabilities